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his study investigated the efects of a pragmatic lifestyle intervention in obese adults with continuous positive airway pressure-
treated obstructive sleep apnoea hypopnoea syndrome (OSAHS). Sixty patients were randomised 1 : 1 to either a 12-week lifestyle
intervention or an advice-only control group. he intervention involved supervised exercise sessions, dietary advice, and the
promotion of lifestyle behaviour change using cognitive-behavioural techniques. Outcomes were assessed at baseline (week 0),
intervention end-point (week 13), and follow-up (week 26). he primary outcome was 13-week change in body mass. Secondary
outcomes included anthropometry, blood-borne biomarkers, exercise capacity, and health-related quality of life. At end-point, the
intervention group exhibited small reductions in body mass (−1.8 [−3.0, −0.5] kg; � = 0.007) and body fat percentage (−1 [−2,
0]%; � = 0.044) and moderate improvements in C-reactive protein (−1.3 [−2.4, −0.2]mg⋅L−1; � = 0.028) and exercise capacity
(95 [50, 139]m; � < 0.001). At follow-up, changes in body mass (−2.0 [−3.5, −0.5] kg; � = 0.010), body fat percentage (−1 [−2,
0]%; � = 0.033), and C-reactive protein (−1.3 [−2.5, −0.1]mg⋅L−1; � = 0.037) were maintained and exercise capacity was further
improved (132 [90, 175]m; � < 0.001). his trial is registered with ClinicalTrials.gov NCT01546792.
1. Introduction
Obstructive sleep apnoea hypopnoea syndrome (OSAHS)
is the most common form of sleep-disordered breathing,
characterised by repetitive nocturnal airway obstruction and
frequent nocturnal arousal from sleep that leads to excessive
daytime sleepiness (EDS). Prevalence surveys suggest that
2% of women and 4% of men at middle age are afected by
this syndrome, which is becoming increasingly commonwith
the current obesity epidemic [1]. he clinical consequences
of repeated airway closures (hypoxaemia, sympathoexci-
tation, and oxidative stress) contribute to the premature
development of cardiovascular disease, speciically ischaemic
heart disease, stroke, and hypertension. Individuals with
OSAHS are oten obese [2] and physically inactive [3], and
epidemiological data indicate an independent relationship
between OSAHS and cardiovascular disease [4]. Obesity is
a key modiiable risk factor for OSAHS [5] with recent
guidelines suggesting that all overweight and obese patients
with OSAHS be encouraged to lose weight [6]. As both
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untreated OSAHS and obesity contribute to the increased
morbidity and mortality, interventions capable of addressing
both should be considered.
Continuous positive airway pressure (CPAP), the pri-
mary therapy for moderate-to-severe OSAHS, improves sub-
jective and objective measures of sleepiness [7] but provides
only day-to-day management of the condition, not a long-
term cure (i.e., withdrawal of CPAP causes symptoms to
return). Moreover, CPAP has minimal efects on patients’
weight or physical activity levels [8] despite increasing exer-
cise capacity [9]. In contrast, intensive lifestyle interventions,
which typically involve very low energy diets (VLEDs),
appear to be efective for initial rapid weight reduction and
can sometimes result in complete remission of OSAHS [10,
11], although steady postintervention weight regaining is
common [12–14]. However, intensive lifestyle interventions
are limited in that they might not be acceptable to many
patients or deliverable within a tax-funded healthcare system.
Further research is needed to explore the impact of lower-
intensity (i.e., more practical) lifestyle interventions on body
mass (i.e., weight) and other important health outcomes in
overweight and obese individuals with OSAHS.
We conducted a randomised controlled trial to deter-
mine the impact of a 12-week pragmatic lifestyle inter-
vention on body mass and other indicators of health and
itness in obese adults who were currently being treated
with CPAP for moderate-to-severe OSAHS. he pragmatic
lifestyle intervention incorporated supervised exercise ses-
sions, dietary education and advice, and the promotion
of lifestyle behaviour change using cognitive-behavioural
techniques. We hypothesised that the intervention group
would have greater improvement in body mass and other
cardiometabolic outcomes, compared with an advice-only
control group.
2. Materials and Methods
2.1. Participants. Patients with OSAHS were recruited from
sleep clinics at Sheield Teaching Hospitals NHS Foundation
Trust. Eligible patients were obese (body mass index (BMI)
> 30 kg⋅m−2) men and women aged 18–85 years with at
least moderate OSAHS (apnoea hypopnoea index (AHI)
> 15 events⋅h−1; oxygen desaturation index > 15 events⋅h−1;
Epworth Sleepiness Scale (ESS) >11) treated with CPAP ther-
apy. Adherence was assessed subjectively using self-report
during history taking (>75% nightly use; >4 hours per night)
and objectively by percentage of nights CPAP was used com-
bined with indices of treatment eicacy (i.e., normalisation of
AHI and ESS). Exclusion criteria were any contraindications
to exercise testing and training such as severe hyperten-
sion, unstable angina, uncontrolled cardiac arrhythmias, and
inability or unwillingness to undertake the commitments
of the study or participation in regular purposeful exercise
(>30min, ≥3 times per week; self-reported). he study was
approved by the South Yorkshire Research Ethics Committee
(09/H1310/74) and all participants providedwritten informed
consent prior to enrolment.
2.2. Sample Size. he primary outcome measure was body
mass (at intervention end-point) because weight loss is a
key focus of management guidelines for overweight and
obese individuals with OSAHS [6], and previous studies have
shown reductions in body mass correlate with improvements
in severity of OSAHS [10, 15]. A total of 60 participants (30
per group) were required to detect a between-group difer-
ence of at least 1.5 kg at intervention end-point, assuming a
standard deviation of 12 kg for body mass [16], a pre-post
correlation for body mass of 0.991 [17], 20% attrition, 90%
power, and a 2-tailed alpha of 0.05.
2.3. Design and Randomisation. his was a nonblinded,
parallel-group, randomised controlled trial. Participants were
allocated 1 : 1 to either a 12-week pragmatic lifestyle inter-
vention or an advice-only control group using a randomi-
sation sequence created by an independent researcher prior
to recruitment (nQuery, Statistical Solutions, USA). he
research team were notiied of group allocation once each
participant completed their baseline assessment. Outcome
measures were assessed before randomisation (week 0), at
intervention end-point (week 13), and ater 13 weeks of
independence (week 26).
2.4. Pragmatic Lifestyle Intervention. Participants random-
ised to the pragmatic lifestyle intervention were invited to
attend supervised exercise sessions at a university exercise
facility within onemile of the treating hospital.he frequency
of exercise sessions was initially three per week. his was
reduced to two per week during weeks 5 to 8 (with a third
exercise session undertaken independently by participants at
their convenience) and then to one per week (with two self-
directed exercise sessions) during weeks 9 to 12. his pattern
was designed to gradually decrease dependence on our facil-
ity, supervision, and expertise and to promote participants’
independent exercise participation, which was reported in
an exercise diary. Exercise sessions lasted approximately
one hour and typically comprised 45 minutes of aerobic
interval training (treadmill walking/jogging, cycling, and
rowing), 15 minutes of resistance training (major muscle
groups), and exercises aimed at improving lexibility and
balance. he aerobic interval training involved alternating
hard and easy exercise bouts at a ratio of 1 : 2 (e.g., 0.5min
hard, 1min easy), progressing to 4 : 1 (e.g., 4min hard,
1min easy) as tolerated. Heart rate and perceived exertion
(RPE, using a 6 to 20 scale; Borg, 1982) were recorded
at the end of hard intervals to facilitate prescription and
monitor progression (RPE: 14–16 for hard bouts and 9–11
for easy bouts). Exercise sessions were individualised and
directed by an exercise physiologist taking into account
participants’ health, mobility, and preferences.he cognitive-
behavioural component of the intervention was integrated
into exercise sessions and involved psychoeducation (based
upon attitudes, experiences, emotions, beliefs, etc.) tailored to
participants’ stage of change and implemented the cognitive-
behavioural processes of change as outlined by the trans-
theoretical model [18]. Such an approach has demonstrated
eicacy in clinical populations previously [19]. Concurrent
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dietary education and advice based on the principles of
the eatwell plate model (http://www.eatwell.gov.uk) were
also integrated into the sessions. A three-day diet diary
was completed and assessed to identify dietary imbalance
and as a tool to set short- and long-term goals. A British
Heart Foundation (BHF) weight loss lealet “So. . . you want
to lose weight for good?” was provided and key concepts
were extracted from it. Participants allocated to the advice-
only control group received a letter explaining their group
allocation, basic written lifestyle advice, and the BHF weight
loss lealet.
2.5. Study Outcomes. Participants’ body mass was measured
in duplicate using a calibrated beam-balance scale (Model
424; Weylux; Hallamshire Scales Ltd., Sheield, UK). Par-
ticipants were minimally dressed and the mean of two
consecutive concordant measurements was used. Secondary
outcomes were BMI; neck, waist, and hip circumferences;
body fat percentage (Bodystat Quadscan 4000, Bodystat Ltd.,
IM99 1DQ); health-related quality of life using the EuroQol
EQ5D-3L questionnaire (EuroQol Executive Oice, 3068 AV
Rotterdam, Netherlands); and exercise capacity using the
incremental shuttle walking test (ISWT; [20]). Fasting venous
blood was collected, centrifuged, separated, and frozen for
subsequent biochemical analysis. Full lipid proile, glucose,
and high-sensitivity C-reactive protein (hs-CRP) were mea-
sured onADVIA 2400 and insulin concentrations onADVIA
Centaur XP (Siemens, 511 Benedict Avenue, Tarrytown, NY).
2.6. Statistical Analyses. he mean diference in change of
body mass between the treatment groups was assessed at
intervention end-point (week 13) by analysis of covariance
(ANCOVA) using baseline body mass as a covariate and
change scores (end-point minus baseline) as the dependent
variable. he adjusted mean diference in change between
groups at week 13 and corresponding 95% conidence interval
(CI) from themodel are presented. All analyses were done on
an intention-to-treat basis with previous observations carried
forward where necessary. he same procedure was used to
assess treatment diference in body mass at follow-up (week
26). Treatment diferences for other outcomes were similarly
analysed using separate ANCOVAs for intervention end-
point (week 13) and follow-up (week 26). All analyses were
carried out in SPSS version 18.0 (SPSS UK Ltd., 2 New Square
(B3 Floor 2), Bedfont Lakes, UK). Statistical tests were at a
two-sided 0⋅05 signiicance level. Analysis of residuals was
undertaken for all regressionmodels in order to assess model
assumptions.
3. Results
3.1. Participant Characteristics. Sixty patients with controlled
OSAHS (ESS: 5.0 [3.0, 6.8]; AHI: 2.4 [1.9, 3.2] events⋅h−1)
that were long-term CPAP users enrolled on the study. Due
to some patients relocation from hospital trusts elsewhere
in the UK, CPAP start dates were only available for 75% of
participants. For these patients,median [range] CPAPhistory
was 1.2 [0.5–10.8] years. All sixty patients had a veriiable
usage history of at least 6 months. Both groups were classi-
ied as obese, normocholesterolaemic, normoglycaemic, and
hyperinsulinaemic. Baseline characteristics are summarised
in Table 1.
3.2. Recruitment, Retention, and Compliance. We invited 481
potentially eligible patients to participate in our study, of
which 123 (26%) responded with interest and underwent
further screening (Figure 1). Of these, 60 (49%) enrolled
giving a recruitment rate of 12%. Although six participants
(10%) withdrew from the study (unrelated health change: � =
2; change in work commitments: � = 2; no reason: � = 2),
97% of assessments (157 of 162) and 96% of exercise sessions
(620 of 648) were attended. No adverse events were recorded
in more than 650 hours of exercise training.
3.3. Anthropometrics. End-point and follow-up data for
anthropometric outcomes are presented in Table 2. he
adjusted mean diference in change in bodymass at interven-
tion end-point (primary outcome) was −1.8 [−3.0, −0.5] kg
(� = 0.007), favouring the intervention group. A similar
diference was maintained at follow-up (−2.0 [−3.5, −0.5] kg;
� = 0.010). hese diferences were accompanied by −0.8
[−1.3, −0.3] and −0.9 [−1.5, −0.3] kg⋅m−2 changes in BMI
(� = 0.002 and � = 0.002, resp.) and −1 [−2, 0] and −1
[−2, 0] % changes in body fat percentage (� = 0.044 and
� = 0.033, resp.). here were no signiicant diferences in
other anthropometric variables.
3.4. Exercise Capacity. Although data were collected for all
participants, seven ISWT datasets (including ISWD and
postexercise heart rate (HR), systolic blood pressure (SBP),
and diastolic blood pressure (DBP)) were excluded because
participants completed the 1020-metre test at one or more
time-points (four at baseline and three at end-point). his
ceiling efect was unexpected and dilutes the true treatment
efect; consequently these patients were excluded from the
analysis.
Despite secure randomisation there was a large chance
imbalance between groups at baseline for distance walked
in the ISWT (475 ± 240 versus 639 ± 198m). Nevertheless,
the adjusted diference in change favoured the intervention
group at end-point (95 [50, 139]m; � < 0.001) and follow-
up (132 [90, 175]m; � < 0.001) at follow-up. his obser-
vation occurred in the absence of any signiicant changes
in any postexercise physiological (SBP, DBP, and HR) or
psychophysiological (RPE) measures (all � > 0.05).
3.5. Biomarkers. Nine patients were unable to provide a
venous blood sample at the baseline assessment. To pre-
vent potential confounding from acute inlammation, eight
datasets were excluded because CRP measurement exceeded
10mg⋅L−1 [21]. Forty-three complete datasets remained (con-
trol: � = 21; intervention: � = 22). here was no change
in serum cholesterol, triglycerides, HDL, LDL, or glucose
at end-point or follow-up. Change in hs-CRP at end-point
favoured the intervention group (−1.3 [−2.4, −0.2]mg⋅L−1,
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Table 1: Baseline group characteristics.
Variable
Control Intervention
� �
Anthropometry
Body mass (kg) 30 118.3 ± 21.9 30 117.4 ± 24.3
Body mass index (kg⋅m−2) 30 39.8 ± 7.0 30 38.9 ± 6.9
Body fat (%) 30 40 ± 9 30 39 ± 8
Neck circumference (cm) 30 45 ± 5 30 44 ± 4
Waist circumference (cm) 30 128 ± 14 30 125 ± 16
Hip circumference (cm) 30 129 ± 14 30 125 ± 15
Cardiometabolic
Resting heart rate (bpm) 30 65 ± 14 30 67 ± 11
Resting systolic BP (mmHg) 30 127 ± 11 30 132 ± 15
Resting diastolic BP (mmHg) 30 72 ± 8 30 75 ± 9
Serum cholesterol (mmol⋅L−1) 21 4.8 [3.4, 6.2] 22 4.7 [3, 6.5]
Serum HDL (mmol⋅L−1) 21 1.2 ± 0.2 22 1.3 ± 0.3
Cholesterol to HDL ratio 21 4.0 ± 0.7 22 4.1 ± 0.7
Serum triglycerides (mmol⋅L−1) 21 1.7 [0.6, 2.8] 22 1.8 [1.2, 2.4]
Serum LDL (mmol⋅L−1) 21 2.7 ± 0.7 22 2.9 ± 1.1
Serum CRP (mg⋅L−1) 21 2.9 [0.3, 5.5] 22 2 [−0.1, 4.0]
Serum glucose (mmol⋅L−1) 21 5.7 ± 1.6 22 5.0 ± 1.1
Serum insulin (mU⋅L−1) 20 29 [7, 51] 20 27 [4, 50]
ISWT
ISWD (m) 27 475 ± 240 26 639 ± 198
Post-ex RPE 27 15 ± 2 26 15 ± 2
Post-ex heart rate (bpm) 27 131 ± 28 26 148 ± 21
Post-ex systolic BP (mmHg) 27 169 ± 29 25 192 ± 31
Post-ex diastolic BP (mmHg) 27 86 ± 15 25 93 ± 11
Quality of life
EuroQol EQ5D-3L VAS 30 58 ± 18 30 64 ± 17
Data are presented as mean ± SD or median [IQR]. BP: blood pressure; HDL: high-density lipoprotein; LDL: low-density lipoprotein; CRP: C-reactive protein;
ISWT: incremental shuttle walk test; ISWD: incremental shuttle walk distance; RPE: Borg rating of perceived exertion; VAS: Visual Analogue Scale.
� = 0.028), and this improvement was maintained at follow-
up (−1.3 [−2.5, −0.1]mg⋅L−1, � = 0.037). here was no
evidence of any signiicant changes in serum insulin over any
of the time periods.
3.6. Quality of Life. here was a reduced proportion of
participants in the intervention group reporting problems
in performing usual activities (e.g., vacuuming, cleaning,
and shopping) at end-point (� = 0.044) but not follow-up
(� = 0.375). here were no changes in the other four EQ5D
domains. Although there was no signiicant change in self-
perceived health score (i.e., EQ Visual Analogue Scale) at
end-point, there was signiicant improvement at follow-up of
9 [2, 16] points (� = 0.017).
4. Discussion
his study demonstrates that a pragmatic lifestyle interven-
tion focused on introducing structured exercise, providing
dietary advice, and combining both with behaviour change
counselling improves body mass, exercise capacity, and a
marker of systemic inlammation in obese adults who were
being treated with CPAP for OSAHS. he programme was
well tolerated by patients, exempliied by excellent attendance
rates and no reported adverse events (inmore than 650 hours
of exercise testing and training).
Although the intervention favoured reductions in body
mass aligned with our hypothesis, the magnitude of these
changes (approx. 2 kg loss at both time-points) was small
and possibly inadequate to provide any clinical beneit. Body
mass reductions in interventions incorporating hypoener-
getic diets are typically greater [22, 23] than thosewithout [24,
25]. VLEDs are oten supplemented with psychological and
dietary support, which rarely alleviates the steady postinter-
ventionweight regain otenobservedwith these interventions
[12, 14]. It is likely that the severe nature of such interventions
produces a rapid weight loss that is unsustainable in the
longer term. Our intervention was designed and used on
the premise that a pragmatic approach based on a slower
rate of weight loss induced by making smaller changes to
behaviour and practising a “healthy lifestyle” could ofermore
sustainable long-term beneit.
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Provisionally assessed for eligibility (n = 550)
Sent a recruitment letter and PIS (n = 481)
No response (n = 131) Responded with disinterest (n = 227)
Responded with interest (n = 123)
Eligible (n = 88)
Randomised (n = 60)
Lifestyle intervention (n = 30)
Did not enrol (n = 28)
Unable to make time commitment (n = 20)
Lost contact with research team (n = 8)
End-point assessment (n = 26) End-point assessment (n = 24)
Follow-up assessment (n = 27) Follow-up assessment (n = 27)
Withdrew from study (n = 3)
Missed assessment (n = 1)
Withdrew from study (n = 3)
Missed assessment (n = 3)
Ineligible at irst pass (n = 69)
BMI < 30kg·m−2 (n = 42)
Subtherapeutic CPAP adherence (n = 18)
Contraindicative comorbidities (n = 9)
Advice-only control (n = 30)
Figure 1: CONSORT low-chart.
Recent meta-analyses have collated evidence on dietary
interventions [26] and exercise-based interventions [27]
in OSAHS. he former reported a weighted mean reduc-
tion in BMI of 4.8 [3.8, 5.9] kg⋅m−2 and in AHI of 23.1
[8.9, 37.3] events⋅h−1. he results of exercise-based interven-
tions appeared less efective, with mean reductions of 1.4
[−2.8, −0.1] kg⋅m−2 and 6.3 [−8.5, −4.0] events⋅h−1 for BMI
and AHI, respectively [27]. However, these latter changes
in BMI and AHI included a study [13] that incorporated a
proprietary VLED alongside the exercise component; this
study alone had a BMI reduction almost double that of the
ive other included studies combined (−6.0 versus −3.3 (� =
5) kg⋅m−2) which distorted the average efect. Despite the
greater weight loss, the improvement in AHI was smaller
than 4 of the 5 other exercise trials. Furthermore, the Barnes
et al. study was a noncontrolled nonrandomised design.
he changes in BMI reported in the current study better
match those in exercise-only trials. he 15 [8, 22] and 21
[14, 27]% improvements in ISWDat end-point and follow-up
are consistent with improvements reported by others [13, 28]
and in our study come atop of any improvement that can
be observed through CPAP therapy alone [9]. Blair [29]
suggested that low cardiorespiratory itness was attributable
to a greater proportion of all-cause mortality (4000 deaths)
than obesity, smoking, and hypercholesterolaemia combined.
his evidence ampliies the importance of improving itness,
even in the absence of changes in “fatness,” in clinical
populations.
Evidence suggests that addressing energy intake is more
eicacious for weight loss than increasing energy expenditure
[30] and that exercise trials that provide dietary advice
only are associated with smaller weight losses than those
providing a VLED [26, 27]. Although we acknowledged
this when designing the study, we feel the severe rate of
weight loss, and typical weight regain seen over time is not
pragmatic enough for introduction into current healthcare
delivery. he premise of making smaller changes in dietary
behaviours that are more sustainable in the long term still
merits investigation and is now supported by the National
Institute for Health and Care Excellence [31] in the UK
as clinically beneicial and cost-efective. All components
of the current intervention were delivered by the same
investigator (JM), who used psychological techniques (such
as motivational interviewing) to elicit core behaviours and
previous barriers to behaviour change in order to cus-
tomise the intervention delivered to promote longer-term
adherence.
Hs-CRP is a systemic marker of inlammation strongly
associated with atherosclerotic plaque development, cardio-
vascular disease risk, and death. Our intervention demon-
strated a signiicant improvement in hs-CRP at end-point
(−1.3mg⋅L−1) that was maintained at follow-up. It has been
shown previously that circulating CRP is elevated in OSAHS
and that efective CPAP therapy can normalise this augmen-
tation [32]. Furthermore, there is evidence to suggest that
exercise can have a beneicial efect on hs-CRP concentration
in humans [33]. As our patients were already compliant
with CPAP therapy, any further reduction in CRP could
relect further decrement in cardiovascular disease risk and
progression.
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Table 2: Raw data by groups and adjusted mean diferences in change at intervention end-point and followup.
Variable
Intervention end-point Followup
(week 13) (week 26)
Control Intervention Adjusted mean dif. (95% CI) �∗ Control Intervention Adjusted mean dif. (95% CI) �∗
Anthropometry
Body mass (kg) 117.9 ± 21.0 115.2 ± 24.3 −1.8 (−3.0, −0.5) 0.006 118.1 ± 21.0 115.1 ± 24.4 −2.0 (−3.5, −0.5) 0.010
Body mass index (kg⋅m−2) 39.8 ± 6.8 38.0 ± 6.9 −0.8 (−1.3, −0.3) 0.002 39.8 ± 6.7 37.9 ± 6.9 −0.9 (−1.5, −0.3) 0.002
Body fat (%) 40 ± 9 37 ± 8 −1 (−2, 0) 0.044 40 ± 9 38 ± 8 −1 (−2, 0) 0.033
Hip circumference (cm) 128 ± 15 123 ± 15 −1 (−2, 0) 0.093 128 ± 15 122 ± 15 −2 (−3, 0) 0.020
Waist circumference (cm) 127 ± 15 123 ± 16 −2 (−4, 0) 0.117 127 ± 15 123 ± 15 −2 (−4, 1) 0.143
Hip circumference (cm) 128 ± 15 123 ± 15 −1 (−2, 0) 0.093 128 ± 15 122 ± 15 −2 (−3, 0) 0.020
Cardiometabolic
Resting heart rate (beats⋅min−1) 66 ± 12 64 ± 12 −5 (−9, −2) 0.002 62 ± 9 63 ± 10 −2 (−6, 1) 0.165
Resting systolic BP (mmHg) 127 ± 13 130 ± 13 0 (−5, 4) 0.893 131 ± 14 133 ± 16 −2 (−7, 4) 0.534
Resting diastolic BP (mmHg) 72 ± 8 74 ± 9 −1 (−4, 2) 0.590 75 ± 8 76 ± 10 −1 (−4, 2) 0.539
Serum cholesterol (mmol⋅L−1) 4.8 [3.2, 6.4] 4.8 [3.5, 6.1] 0.1 (−0.2, 0.3) 0.575 4.4 [2.5, 6.3] 4.6 [3.6, 5.5] −0.1 (−0.5, 0.3) 0.645
Serum HDL (mmol⋅L−1) 1.2 ± 0.2 1.2 ± 0.3 0.0 (−0.1, 0.9) 0.569 1.2 ± 0.3 1.2 ± 0.2 −0.1 (−0.2, 0) 0.241
Serum LDL (mmol⋅L−1) 2.7 ± 0.8 2.9 ± 1 0 (−0.2, 0.3) 0.731 2.6 ± 0.9 2.8 ± 0.9 0 (−0.3, 0.3) 0.814
Serum CRP (mg⋅L−1) 3.3 [0.1, 6.5] 1.4 [−0.7, 3.5] −1.3 (−2.4, −0.2) 0.028 3.2 [−2.1, 8.5] 1.8 [0.6, 3] −1.3 (−2.5, −0.1) 0.037
Serum glucose (mmol⋅L−1) 5.7 ± 1.9 4.8 ± 0.5 −0.3 (−0.9, 0.2) 0.224 5.7 ± 1.9 4.8 ± 0.8 −0.3 (−0.9, 0.3) 0.267
ISWT
ISWD (m) 475 ± 250 724 ± 193 95 (50, 139) <0.001 471 ± 240 737 ± 179 132 (90, 175) <0.001
Quality of life
EQVAS 63 ± 19 60 ± 20 3 (−4, 10) 0.385 69 ± 18 72 ± 16 9 (2, 16) 0.017
Data are presented asmean± SDormedian [IQR]. BP: blood pressure;HDL: high-density lipoprotein; LDL: low-density lipoprotein; CRP: C-reactive protein; ISWT: incremental shuttle walk test; ISWD: incremental
shuttle walk distance; RPE: Borg rating of perceived exertion; EQVAS: EuroQol Visual Analogue Scale; �∗: � value adjusted for baseline score.
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Improvements in exercise capacity were not surprising
indings considering the design of our study. he key inding
here was that, ater 13 weeks of independence, improve-
ments in exercise capacity were not only maintained but
further improved upon. Although we included nomeasure of
exercise behaviour during the independence period, further
improvements are probably relective of continued regular
exercise training, which was mentioned anecdotally by par-
ticipants during assessments.
Limitations. Although a metric of OSAHS severity was not
included in the current study for inancial and logistical
reasons, it was thought that changes in body mass could be
a surrogate marker for changes in OSAHS severity. Improve-
ments in OSAHS in the absence of weight loss have been
demonstrated by other groups, coupled with evidence that
sedentary behaviour and low cardiorespiratory itness could
pose a greater public health concern than obesity, suggests
that the improvements in exercise capacity demonstrated in
the current study should not be underestimated. Although
the current study is powered for changes in body mass,
we do not know if it was adequately powered for the
secondary outcomemeasures, so these indingsmust be inter-
preted with caution. Other limitations include the single-
centre study design and nonblinded assessments, which were
unavoidable because of resource limitation. However, we
have demonstrated an acceptable and deliverable programme
with positive outcomes that should, in combination with
enhanced dietary intervention, be further investigated in a
larger OSAHS group.
5. Conclusion
A pragmatic lifestyle intervention in OSAHS has been shown
to improve cardiometabolic outcomes in obese adults treated
with CPAP for OSAHS. his approach is one that could be
deliverable within the UK (and other) healthcare systems.
Further research is required to further investigate the clinical
eicacy and cost-efectiveness of pragmatic lifestyle interven-
tions in OSAHS.
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